NIHR Clinical Research Network achieves 25 first global patients in one year
The NIHR Clinical Research Network has reached a milestone in
study set up achievements by recruiting 25 first global patients in
commercial studies in the 2013/14 financial year.
The 25th study to make this highly sought after achievement was
at Manchester Royal Eye Hospital. The
study aims to build on existing safety and effectiveness data for
ocriplasmin, a treatment for some people with the rare eye
condition, vitreomacular traction.
registry study to characterise genetic and pathway biomarkers in
Noonan syndrome and other RASopathy patients managed by
researchers at the Manchester Centre for Genomic Medicine at CMFT
was also part of the list.
Recruiting a first global patient is a key performance indicator
for the life-sciences industry in clinical research delivery as it
shows the Network can support the rapid set-up of studies.
Since the Network started to record first global patients, it
has achieved 42 in total. But it is during the past financial year
that it has seen a rapid upturn in the number of studies to make
the achievement. This is down to the reduction of study set-up
Commenting on the news, Dr Jonathan Sheffield, Chief Executive
Officer of the Clinical Research Network, said: "Congratulations to
Manchester Royal Eye Hospital for successfully recruiting a first
global patient and to each of the studies that have made up this
fantastic milestone of 25 first global patients.
"Achieving a first global patient shows that the UK has the
infrastructure to compete on the international stage in terms of
clinical research study set-up. The Network is driving down the
time it takes to set up a study in the UK and this in turn is being
rewarded with a record number of these achievements."
Five of the studies that have achieved first global patient were
sponsored by Novartis UK. These have included studies in to
psoriatic arthritis, chronic obstructive pulmonary disease, acute
heart failure and psoriasis.
Darren Gerrard is a Senior Clinical Study Manager at Novartis
UK, said: "What we excel at is being the fastest country globally
to start our trials and get patients on to new treatments. This is
encouraging more clinical trials to be placed in the UK, when many
similar companies are pulling out.
"Many trusts are now winning more commercial work due to their
ability to quickly agree costs in line with the costing template
which in turn has led to excellent metrics on start-up and giving
them more time to recruit to target. I cannot emphasis enough how a
consistent approach to site set-up in line with NIHR guidance has
become. We set ourselves above the competition by aligning site
costs and using standardised contracts.
"This is all about partnership with our NIHR and local research
Network colleagues and team work, working better together
nationally which will continue our success in a difficult
marketplace. Fast start up can only lead to more trials placed in
the UK, better patient outcomes and experience of new
Professor Dame Sally C. Davies, Chief Medical Officer and Chief
Scientific Adviser at the Department of Health said: "Rapid study
set-up is integral to attracting new studies and companies to the
UK. This is a key aim of the NIHR and plays an important role in
the Government's Strategy for UK Life Sciences."
To see a full list of studies that have achieved first global
patient and to find out more about commercial contract studies
supported by the Network, visit www.supportmystudy.nihr.ac.uk.